

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Telerehabilitation programs for cancer patients and survivors: a protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058981
Article Type:	Protocol
Date Submitted by the Author:	03-Nov-2021
Complete List of Authors:	He, Yu; Shengjing Hospital of China Medical University, Department of Rehabilitation; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation Han, Xiaochai; Shengjing Hospital of China Medical University, Department of Rehabilitation Zou, Wenchen; Shengjing Hospital of China Medical University, Department of Rehabilitation Liu, Xuemin; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation Sun, Nianyi; Shanghai Fourth People's Hospital, Department of Rehabilitation Zhou, Fenghua; Shengjing Hospital of China Medical University, Department of Rehabilitation; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation
Keywords:	REHABILITATION MEDICINE, ONCOLOGY, EDUCATION & TRAINING (see Medical Education & Training), HEALTH SERVICES ADMINISTRATION & MANAGEMENT, SPORTS MEDICINE

SCHOLARONE™
Manuscripts

Telerehabilitation programs for cancer patients and survivors: a protocol for a systematic review

Yu He,^{1, 2} Xiaochai Han,¹ Wenchen Zou,¹ Xuemin Liu,² Nianyi Sun,^{2, 3} Fenghua Zhou^{1, 2*}

¹Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110134, China.

²Department of Physical Medicine and Rehabilitation, The Second Clinical College, China Medical University, Shenyang 110122, China.

³Department of Rehabilitation, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

* Corresponding author

Key words: telerehabilitation; telehealth; cancer; rehabilitation; systematic review; protocol

ABSTRACT

Introduction The global cancer burden is a major public health problem. Cancer rehabilitation is an essential component of survivorship care to prevent complications, decrease symptoms, improve functioning and quality of life (QOL). In addition to

1
2
3
4 preexisting challenges, the coronavirus disease 19 (COVID-19) pandemic has greatly
5
6 impacted cancer rehabilitation programs and their delivery to patients. This
7
8 comprehensive systematic review will assess the efficacy and safety of
9
10 telerehabilitation on functional outcomes and QOL in cancer patients and survivors.
11
12

13
14 **Methods and analysis** This protocol was developed in line with the Preferred
15
16 Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P).
17
18 The following key electronic bibliographic databases will be searched from inception
19
20 to April 2021: MEDLINE, EMBASE, CINAHL, CENTRAL, and PEDro. We will
21
22 include randomised controlled trials (RCTs) published in English that examine the
23
24 effects of telerehabilitation programs on cancer patients and survivors. The concepts of
25
26 ‘intervention’, ‘participants’ and ‘study design’ will be combined with the ‘AND’
27
28 operator in our search strategy. Two reviewers will independently complete the study
29
30 screening, selection, data extraction, and quality rating. The PEDro scale will be used
31
32 to assess the methodological quality of the included studies. A narrative or quantitative
33
34 synthesis will be conducted based on the final data. The planned start and end dates for
35
36 the study were 1 March 2021 and 1 May 2022.
37
38
39
40
41
42
43
44

45 **Ethics and dissemination** Ethical approval will not be required for this review. The
46
47 results of this review will be disseminated in a peer-reviewed journal.
48
49

50 **Registration details** PROSPERO International prospective register of systematic
51
52 review registration number: CRD42021243467.
53
54
55
56
57

58 **Strengths and limitations of this study**
59
60

- This protocol and the final review will be developed in accordance with the PRISMA and recommendations from the Cochrane handbook.
- Five key databases will be searched: MEDLINE, EMBASE, CINAHL, CENTRAL, and PEDro.
- Two reviewers will independently complete the study screening, selection, data extraction, and quality rating. Possible disagreement will be resolved by discussion or with consultation of a third author.
- The different type, site and stage of cancer and anticancer treatment may lead to a large degree of heterogeneity.

INTRODUCTION

Cancer ranks as the second leading cause of death and an important barrier to increasing life expectancy worldwide.^{1, 2} The magnitude of cancer is rapidly growing globally, it is estimated that 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020.² The global cancer burden is predicted to be 22.2 million new cases in 2030 and 28.4 million in 2040.^{2, 3}

Cancer diagnosis, progression as well as aggressive treatment often make cancer patients and survivors suffer functional impairments and disabilities, both physically and psychologically, which may lead into a decreased health-related quality of life (QOL).⁴ Therefore, cancer rehabilitation, an essential component of survivorship care, is needed to prevent complications, decrease symptoms, improve functioning and QOL, attain independence, and improve prognosis.⁵⁻⁷ However, several challenges are present

1
2
3
4 in the movement to expand traditional face to face cancer rehabilitation, especially in
5
6 developing countries.^{7, 8} Rehabilitation programs are often long in duration and
7
8 resource intensive, while access to cancer rehabilitation services is limited due to lack
9
10 of specialized providers (most of whom clustered in tertiary care centers), travel
11
12 burdens, financial burdens, time constraints, physical limitations, psychological and
13
14 emotional burdens along with other hardships.⁷⁻¹² A possible solution to address these
15
16 challenges is to provide telerehabilitation services. Additionally, the coronavirus
17
18 disease 2019 (COVID-19) pandemic has broadly disrupted medical care and
19
20 accelerated the growth of telerehabilitation services for cancer patients and survivors.^{9,}
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

13
As a domain of telehealth, telerehabilitation makes use of a variety of information and communication technologies or commonly referred to as “telehealth” technologies, to deliver rehabilitation services to people over a distance, closing geographic, physical, and motivational gaps.^{14, 15} Under this term, the services can include evaluation, assessment, monitoring, prevention, intervention, supervision, education, consultation, and coaching.^{14, 15} The information and communication technologies used in telerehabilitation may integrate but are not limited to e-mail programs, text messaging, telephone follow-up, video and audio conferencing, wearable technologies, sensor technologies, mobile health applications, patient portals or platforms, virtual reality programs, therapeutic gaming technologies, and robotics.¹⁴⁻¹⁷ There has been increasing interest in the use of this burgeoning field of telerehabilitation services as technologies continue to evolve.¹⁵ Many examples in the current literature have explored the

1
2
3
4 acceptability, feasibility, efficacy and cost-effectiveness of telerehabilitation in
5
6 neurological,¹⁸⁻²⁰ cardiopulmonary,²¹⁻²⁴ musculoskeletal,²⁵⁻²⁷ and postoperative^{28, 29}
7
8 rehabilitation services, showing the promise in this field.
9
10

11
12 In recent years, there have been a proliferation of literature reporting telehealth-
13
14 related oncology research, most of which focusing on feasibility and technical
15
16 properties of technologies, diagnosis and treatment, user experience, or symptom
17
18 monitoring.³⁰ Earlier systematic reviews regarding telehealth interventions in this
19
20 territory involved the application research on current technology and services
21
22 provided,^{31, 32} acceptability studies,³³ studies focusing on self-management program,^{34,}
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35 studies targeting a certain type of tumor.³⁶⁻³⁹ In addition, clinical effectiveness
measures were mostly psychosocial, symptomatic or QOL-related.⁴⁰⁻⁴⁶

11
12 However, in the field of telerehabilitation programs for cancer patients and
13
14 survivors, there are only a small number of evidences and they are with diverse
15
16 emphasis. Two studies have systematically reviewed evidence regarding the benefits of
17
18 psycho-educational interventions using telecommunication technologies for cancer
19
20 patients,^{47, 48} with hopeful findings. A recent review explored and confirmed the
21
22 usefulness of telehealth approach for occupational therapy practice in cancer
23
24 survivors,⁴⁹ while the results of another two reviews focusing on remotely delivered
25
26 physical activity were not that positive as expected.^{50, 51} Additionally, the COVID-19
27
28 pandemic has expedited the transition of cancer rehabilitation programs to a remote-
29
30 delivery format, which increases the urgency of understanding the efficacy and safety
31
32 of such a model. Given the current status of the research in this field, this
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 comprehensive systematic review aims to study the efficacy and safety of
5
6 telerehabilitation on functional outcomes and QOL in cancer patients and survivors,
7
8 and we hope that this study will be helpful for future work.
9

10 11 **METHODS**

12 **Study registration**

13
14
15 This protocol has been registered on Prospero (registration number: CRD42021243467)
16
17 and was developed according to the PRISMA-P.⁵² The final systematic review will be
18
19 conducted in line with the Preferred Reporting Items for Systematic Review and Meta-
20
21 Analysis (PRISMA) statement,⁵³ and the guidance of the Cochrane Handbook for
22
23 Systematic Reviews of Interventions.⁵⁴
24
25
26
27
28
29

30 **Inclusion criteria for study selection**

31
32 Studies will be included in final review if they meet the following inclusion criteria:
33
34

35 **Types of participants**

36
37 Adult cancer patients or survivors (≥ 18 years of age) were considered irrespective of
38
39 sex, race, site of cancer, type and stage of cancer, and type of anticancer treatment
40
41 received.
42
43
44

45 **Types of interventions**

46
47 Participants in the experimental group received telerehabilitation programs. We will
48
49 include interventions if they met with the following definition of telerehabilitation: "the
50
51 delivery of rehabilitation services via information and communication technologies".¹⁴,
52
53

54
55 ¹⁵ Telehealth interventions for the purposes of patient education or communication,
56
57 self-administered management without therapist supervision, remote symptoms or
58
59
60

1
2
3
4 physiological parameters monitoring alone (i.e. telemonitoring), without delivery of
5
6 cancer rehabilitation, were excluded.
7
8

9 **Types of comparator(s)/control**

10
11 We will include studies that compare telerehabilitation programs with face to face
12
13 rehabilitation treatments, such as center-based (outpatient) rehabilitation, inpatient
14
15 rehabilitation or home visits, or a no rehabilitation control.
16
17
18

19 **Types of outcome measures**

20 *Primary outcomes*

21
22
23
24
25 1. Health-related QOL such as Functional Assessment of Cancer Therapy General
26
27 (FACT-G) and related site-specific cancer module, The European Organization for
28
29 Research and Treatment of Cancer - Core Quality of Life Questionnaire, version 3.0
30
31 (EORTC QLQ-C30) and related site-specific cancer module, Short Form (36) Health
32
33 Survey (SF-36).
34
35
36

37
38 2. Physical function which were measured using 6-min walk, timed up-and-go,
39
40 cardiopulmonary exercise tests (CPETs), moderate and vigorous physical activity
41
42 (MVPA), strength, flexibility, endurance, and related validated tests and scales, etc.
43
44

45 *Secondary outcomes*

46
47
48 Cancer-related symptoms such as pain, fatigue, nausea/vomiting, dyspnoea, sleep
49
50 disturbances, appetite loss, constipation, and diarrhoea. Anxiety and depression,
51
52 anthropometrics, biomarker analysis, survivorship, adverse events, and compliance.
53
54

55
56 These outcomes should be measured by validated tests and scales.
57

58 **Types of studies**

1
2
3
4 Randomised controlled trials (RCTs) reported in English and published as full text will
5
6 be included. Studies will be excluded if they were quasi-randomized trials and other
7
8 types of studies such as animal research, uncontrolled trials or case reports, conference
9
10 proceedings/abstracts, dissertations, reported in books, or with no available data for
11
12 analysis.
13
14
15

16 **Search methods for the identification of studies**

17
18
19 The following key electronic bibliographic databases will be searched from inception
20
21 to April 2021: MEDLINE, EMBASE, CINAHL, Cochrane Central Register of
22
23 Controlled Trials (CENTRAL), and Physiotherapy Evidence Database (PEDro). The
24
25 RCTs that evaluate the effectiveness of telerehabilitation programs for cancer patients
26
27 and survivors by setting comparators/controls mentioned above will be included. The
28
29 strategy will search for 'telerehabilitation' AND 'neoplasms' AND 'RCTs'. For each
30
31 of the 'intervention', 'participants' and 'study design' concept, we will combine
32
33 synonyms and MeSH terms with the 'OR' operator. The proposed search strategy for
34
35 MEDLINE via Ovid is listed in online supplemental material appendix 1. This strategy
36
37 will be adapted for use in the other databases. In addition, we will check the reference
38
39 lists of all the included trials and relevant systematic reviews to identify any potentially
40
41 eligible studies.
42
43
44
45
46
47
48
49

50 **Data collection**

51 **Study selection**

52
53
54 The retrieved records will be imported into the bibliographic software Endnote (V.X9).
55
56
57 Any duplicates will be identified and removed using Endnote. Two review authors (YH
58
59
60

1
2
3
4 and NS) will independently screen the titles, abstracts and keywords of the remaining
5
6 articles with predefined criteria. After preliminary screening, we will retrieve the full-
7
8 text of all potentially eligible articles and two review authors (YH and NS) will
9
10 independently review them in detail, and the explicit reasons for exclusion of ineligible
11
12 studies will be recorded. We will resolve any disagreement through discussion or
13
14 consultation with a third author (FZ). The flow chart of the selection procedure is
15
16 presented in figure 1.
17
18
19
20
21

22 **Data extraction and management**

23
24 Two review authors (YH and NS) will use a pre-designed data collection Excel form to
25
26 extract the following data from the included studies independently:
27
28

- 29
30 1. General information: article title, journal, publication year, first author,
31
32 corresponding author, country of study, aim of study, trial registration, study funding
33
34 source, and possible conflicts of interest.
35
36
- 37
38 2. Study characteristics: study design, method of randomization, method of blinding,
39
40 allocation concealment, completeness of outcome data.
41
42
- 43
44 3. Participants: sample size, baseline participant characteristics, site of cancer, type and
45
46 stage of cancer, type of anticancer treatment, comorbidities.
47
- 48
49 4. Interventions: type, frequency, intensity and duration for telerehabilitation and
50
51 comparators.
52
- 53
54 5. Outcomes: outcome measurements, time points reported, follow-up duration, adverse
55
56 events.
57

58 **Methodological quality assessment**

1
2
3
4 Two review authors (YH and NS) will independently assess the methodological quality
5
6 of each selected study using the Physiotherapy Evidence Database (PEDro) scale.⁵⁵
7
8
9 Possible disagreement will be resolved by discussion or with consultation of a third
10
11 author (FZ). The PEDro scale is considered to be a valid and reliable measure of the
12
13 methodological quality of RCTs in physiotherapy.^{55, 56} This scale consists of 11 criteria,
14
15 and considering that the 1st item is not utilized to calculate the score, the scale has a
16
17 possible range of 0 to 10, with higher scores suggesting higher quality. On this scale,
18
19 the cut-off for high quality of methodology is a score ≥ 6 points.⁵⁵
20
21
22
23
24

25 **Data analysis and synthesis**

26
27 The Cochrane Review Manager Version 5 software will be used for meta-analysis. In
28
29 our study, a meta-analysis concerning the effect of telerehabilitation programs will be
30
31 conducted if at least two studies used the homogeneous outcome measure or measured
32
33 similar constructs.
34
35
36

37
38 The outcome indicators involved in this study are mostly continuous data,
39
40 standardized mean differences (SMD) as well as 95% confidence interval (CI) will be
41
42 computed.
43
44

45
46 The chi-squared test and I^2 statistic will be used to assess heterogeneity across
47
48 studies.^{54, 57} If $p > 0.1$, and $I^2 < 50\%$, a fixed-effect model will be adopted for data
49
50 combination; if $p > 0.1$, and $I^2 \geq 50\%$, a random-effect model will be adopted for data
51
52 combination, and obvious heterogeneity is considered between the studies; if $p \leq 0.1$,
53
54 statistical significance is considered in this case, and a subgroup analysis or a narrative
55
56 description will be performed.⁵⁴
57
58
59
60

1
2
3
4 When sufficient data are available, prespecified subgroups will be conducted
5
6 based on gender; comorbid condition; the type, frequency, intensity and duration of
7
8 telerehabilitation programs; the site, type and stage of cancer, to explore factors that
9
10 might be related to the strength of the effect. In addition, if data permitted, sensitivity
11
12 analyses will be performed to examine the robustness and reliability of the results by
13
14 omitting specific trials from the overall analysis.
15
16
17

18
19 If more than 10 trials are included in a result of a meta-analysis, we will construct
20
21 a funnel plot to explore the potential publication bias.
22
23

24
25 The overall quality of each summarised evidence will be evaluated using Grading
26
27 of Recommendations Assessment, Development and Evaluation (GRADE) system at
28
29 four levels: high, moderate, low or very low.⁵⁸ Two review authors (YH and NS) will
30
31 independently assess the quality of the evidence using GRADEpro software
32
33 (<https://gradepr.org>), and possible discrepancies will be resolved through discussion
34
35 or consultation with a third author (FZ).
36
37
38

39 40 **Patient and public involvement**

41
42 This protocol for a systematic review does not directly involve patients or the general
43
44 public. The data will be collected from published articles retrieved from the main
45
46 databases and manual searches.
47
48

49 50 **Ethics and dissemination**

51
52 Ethical approval will not be required for the performance of this review protocol. The
53
54 results of the final review will be disseminated in a peer-reviewed journal.
55
56

57 58 **DISCUSSION**

1
2
3
4 The COVID-19 pandemic has prompted calls for accelerated introduction of alternative
5
6 models of cancer rehabilitation service delivery that include home-based
7
8 telerehabilitation.^{9, 13} This review will systematically and comprehensively assess the
9
10 efficacy and safety of telerehabilitation programs on functional outcomes and QOL in
11
12 cancer patients and survivors. This protocol provides with the current status of the
13
14 research in this field, and we hope that the final review will be helpful to support
15
16 decision-making related to health policies and rehabilitation programs.
17
18
19
20
21
22
23

24
25 **Acknowledgments** We thank the anonymous reviewers for their helpful comments.
26

27 **Contributors** YH, NS and FZ contributed to the conception and design of the study.
28

29
30 NS registered the protocol in the PROSPERO database. YH drafted the protocol. FZ
31
32 revised the protocol critically for important intellectual content. XH, WZ and XL
33
34 designed the search strategy. YH, XH, WZ, XL, NS and FZ participated in the design
35
36 of data acquisition, analysis and interpretation. All authors have read and approved the
37
38 final protocol. FZ is the guarantor of this protocol.
39
40
41
42

43 **Funding** This research did not receive any specific grant from funding agencies in the
44
45 public, commercial, or not-for-profit sectors.
46
47

48 **Competing interests:** We declare that there is no conflict of interest regarding the
49
50 publication of this protocol.
51
52

53 **Patient consent for publication** Not required.
54

55
56 **Ethical approval:** Ethical approval will not be required for the performance of this
57
58 protocol for a systematic review.
59
60

Data sharing No additional data are available.

REFERENCES

1. World Health Organization (WHO). Cancer. Available: <https://www.who.int/zh/news-room/fact-sheets/detail/cancer> [Accessed 30 March 2021].
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71(3):209-49.
3. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. *Lancet Oncol* 2012;13(8):790-801.
4. Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. *CA Cancer J Clin* 2013;63(5):295-317.
5. Alfano CM, Ganz PA, Rowland JH, et al. Cancer survivorship and cancer rehabilitation: revitalizing the link. *J Clin Oncol* 2012;30(9):904-6.
6. Stout NL, Silver JK, Raj VS, et al. Toward a National Initiative in Cancer Rehabilitation: Recommendations From a Subject Matter Expert Group. *Arch Phys Med Rehabil* 2016;97(11):2006-15.
7. Stout NL, Santa Mina D, Lyons KD, et al. A systematic review of rehabilitation and exercise recommendations in oncology guidelines. *CA Cancer J Clin* 2021;71(2):149-75.
8. Anwar SL, Adistyawan G, Wulaningsih W, et al. Rehabilitation for Cancer Survivors: How We Can Reduce the Healthcare Service Inequality in Low- and Middle-Income Countries. *Am J Phys Med Rehabil* 2018;97(10):764-71.

- 1
2
3
4 9. Chang P, Asher A. Cancer Telerehabilitation. *Phys Med Rehabil Clin N Am* 2021;32(2):277-
5
6 89.
7
8
- 9 10. Fillon M. Patients with advanced-stage cancer may benefit from telerehabilitation. *CA Cancer*
10
11 *J Clin* 2019;69(5):349-50.
12
13
- 14 11. Cheville AL, Mustian K, Winters-Stone K, et al. Cancer Rehabilitation: An Overview of
15
16 Current Need, Delivery Models, and Levels of Care. *Phys Med Rehabil Clin N Am*
17
18 2017;28(1):1-17.
19
20
- 21 12. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical
22
23 and mental health-related quality of life among US cancer survivors. *Cancer* 2016;122(8):283-
24
25 9.
26
27
- 28 13. Nekhlyudov L, Duijts S, Hudson SV, et al. Addressing the needs of cancer survivors during
29
30 the COVID-19 pandemic. *J Cancer Surviv* 2020;14(5):601-6.
31
32
- 33 14. Richmond T, Peterson C, Cason J, et al. American Telemedicine Association's Principles for
34
35 Delivering Telerehabilitation Services. *Int J Telerehabil* 2017;9(2):63-8.
36
37
- 38 15. Galea MD. Telemedicine in Rehabilitation. *Phys Med Rehabil Clin N Am* 2019;30(2):473-83.
39
40
- 41 16. Tenforde AS, Hefner JE, Kodish-Wachs JE, et al. Telehealth in Physical Medicine and
42
43 Rehabilitation: A Narrative Review. *PM R* 2017;9(5S):S51-8.
44
45
- 46 17. Pramuka M, van Roosmalen L. Telerehabilitation technologies: accessibility and usability. *Int*
47
48 *J Telerehabil* 2009;1(1):85-98.
49
50
- 51 18. Laver KE, Adey-Wakeling Z, Crotty M, et al. Telerehabilitation services for stroke. *Cochrane*
52
53 *Database Syst Rev* 2020;1(1):CD010255.
54
55
- 56 19. Hailey D, Roine R, Ohinmaa A, et al. The status of telerehabilitation in neurological
57
58
59
60

- 1
2
3
4 applications. *J Telemed Telecare* 2013;19(6):307-10.
5
6
7 20. Ownsworth T, Arnautovska U, Beadle E, et al. Efficacy of Telerehabilitation for Adults With
8
9 Traumatic Brain Injury: A Systematic Review. *J Head Trauma Rehabil* 2018;33(4):E33-46.
10
11
12 21. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease.
13
14 *Cochrane Database Syst Rev* 2021;1(1):CD013040.
15
16
17 22. Taito S, Yamauchi K, Kataoka Y. Telerehabilitation in Subjects With Respiratory Disease: A
18
19 Scoping Review. *Respir Care* 2021;66(4):686-98.
20
21
22 23. Hwang R, Bruning J, Morris N, et al. A Systematic Review of the Effects of Telerehabilitation
23
24 in Patients With Cardiopulmonary Diseases. *J Cardiopulm Rehabil Prev* 2015;35(6):380-9.
25
26
27 24. Subedi N, Rawstorn JC, Gao L, et al. Implementation of Telerehabilitation Interventions for
28
29 the Self-Management of Cardiovascular Disease: Systematic Review. *JMIR Mhealth Uhealth*
30
31 2020;8(11):e17957.
32
33
34
35 25. Cottrell MA, Galea OA, O'Leary SP, et al. Real-time telerehabilitation for the treatment of
36
37 musculoskeletal conditions is effective and comparable to standard practice: a systematic
38
39 review and meta-analysis. *Clin Rehabil* 2017;31(5):625-38.
40
41
42
43 26. Srikesavan C, Bryer C, Ali U, et al. Web-based rehabilitation interventions for people with
44
45 rheumatoid arthritis: A systematic review. *J Telemed Telecare* 2019;25(5):263-75.
46
47
48 27. Xie SH, Wang Q, Wang LQ, et al. Effect of Internet-Based Rehabilitation Programs on
49
50 Improvement of Pain and Physical Function in Patients with Knee Osteoarthritis: Systematic
51
52 Review and Meta-analysis of Randomized Controlled Trials. *J Med Internet Res*
53
54 2021;23(1):e21542.
55
56
57
58 28. van Egmond MA, van der Schaaf M, Vredeveld T, et al. Effectiveness of physiotherapy with
59
60

- 1
2
3
4 telerehabilitation in surgical patients: a systematic review and meta-analysis. *Physiotherapy*
5
6 2018;104(3):277-98.
7
8
9 29. Jiang S, Xiang J, Gao X, et al. The comparison of telerehabilitation and face-to-face
10
11 rehabilitation after total knee arthroplasty: A systematic review and meta-analysis. *J Telemed*
12
13 *Telecare* 2018;24(4):257-62.
14
15
16 30. Rising KL, Ward MM, Goldwater JC, et al. Framework to Advance Oncology-Related
17
18 Telehealth. *JCO Clin Cancer Inform* 2018;2:1-11.
19
20
21 31. Ayyoubzadeh SM, R Niakan Kalhori S, Shirkhoda M, et al. Supporting colorectal cancer
22
23 survivors using eHealth: a systematic review and framework suggestion. *Support Care Cancer*
24
25 2020;28(8):3543-55.
26
27
28 32. Schaffer K, Panneerselvam N, Loh KP, et al. Systematic Review of Randomized Controlled
29
30 Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. *J*
31
32 *Natl Compr Canc Netw* 2019;17(1):57-63.
33
34
35 33. Sotirova MB, McCaughan EM, Ramsey L, et al. Acceptability of online exercise-based
36
37 interventions after breast cancer surgery: systematic review and narrative synthesis. *J Cancer*
38
39 *Surviv* 2021;15(2):281-310.
40
41
42 34. Huang J, Han Y, Wei J, et al. The effectiveness of the Internet-based self-management program
43
44 for cancer-related fatigue patients: a systematic review and meta-analysis. *Clin Rehabil*
45
46 2020;34(3):287-98.
47
48
49 35. Xu A, Wang Y, Wu X. Effectiveness of e-health based self-management to improve cancer-
50
51 related fatigue, self-efficacy and quality of life in cancer patients: Systematic review and meta-
52
53 analysis. *J Adv Nurs* 2019;75(12):3434-47.
54
55
56
57
58
59
60


- 1
2
3
4 36. Triberti S, Savioni L, Sebri V, et al. eHealth for improving quality of life in breast cancer
5
6 patients: A systematic review. *Cancer Treat Rev* 2019;74:1-14.
7
8
9 37. Dorri S, Asadi F, Olfatbakhsh A, et al. A Systematic Review of Electronic Health (eHealth)
10
11 interventions to improve physical activity in patients with breast cancer. *Breast Cancer*
12
13 2020;27(1):25-46.
14
15
16 38. Chen YY, Guan BS, Li ZK, et al. Effect of telehealth intervention on breast cancer patients'
17
18 quality of life and psychological outcomes: A meta-analysis. *J Telemed Telecare*
19
20 2018;24(3):157-67.
21
22
23 39. Pang L, Liu Z, Lin S, et al. The effects of telemedicine on the quality of life of patients with
24
25 lung cancer: a systematic review and meta-analysis. *Ther Adv Chronic Dis*
26
27 2020;11:2040622320961597.
28
29
30 40. Seiler A, Klaas V, Tröster G, et al. eHealth and mHealth interventions in the treatment of
31
32 fatigued cancer survivors: A systematic review and meta-analysis. *Psychooncology*
33
34 2017;26(9):1239-53.
35
36
37 41. Fridriksdottir N, Gunnarsdottir S, Zoëga S, et al. Effects of web-based interventions on cancer
38
39 patients' symptoms: review of randomized trials. *Support Care Cancer* 2018;26(2):337-51.
40
41
42 42. Hernandez Silva E, Lawler S, Langbecker D. The effectiveness of mHealth for self-
43
44 management in improving pain, psychological distress, fatigue, and sleep in cancer survivors:
45
46 a systematic review. *J Cancer Surviv* 2019;13(1):97-107.
47
48
49 43. Buneviciene I, Mekary RA, Smith TR, et al. Can mHealth interventions improve quality of life
50
51 of cancer patients? A systematic review and meta-analysis. *Crit Rev Oncol Hematol*
52
53 2021;157:103123.
54
55
56
57
58
59
60

- 1
2
3
4 44. Agboola SO, Ju W, Elfiky A, et al. The effect of technology-based interventions on pain,
5
6 depression, and quality of life in patients with cancer: a systematic review of randomized
7
8 controlled trials. *J Med Internet Res* 2015;17(3):e65.
9
10
11 45. Larson JL, Rosen AB, Wilson FA. The Effect of Telehealth Interventions on Quality of Life
12
13 of Cancer Patients: A Systematic Review and Meta-Analysis. *Telemed J E Health*
14
15 2018;24(6):397-405.
16
17 46. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality of life of
18
19 cancer survivors: A systematic review and meta-analysis. *Health Informatics J*
20
21 2020;26(2):1060-78.
22
23 47. Bártolo A, Pacheco E, Rodrigues F, et al. Effectiveness of psycho-educational interventions
24
25 with telecommunication technologies on emotional distress and quality of life of adult cancer
26
27 patients: a systematic review. *Disabil Rehabil* 2019;41(8):870-78.
28
29
30 48. Wang Y, Lin Y, Chen J, et al. Effects of Internet-based psycho-educational interventions on
31
32 mental health and quality of life among cancer patients: a systematic review and meta-analysis.
33
34 *Support Care Cancer* 2020;28(6):2541-52.
35
36
37 49. Hwang NK, Jung YJ, Park JS. Information and Communications Technology-Based
38
39 Telehealth Approach for Occupational Therapy Interventions for Cancer Survivors: A
40
41 Systematic Review. *Healthcare (Basel)* 2020;8(4):355.
42
43
44 50. Ibeggazene S, Turner R, Rosario D, et al. Remote interventions to improve exercise behaviour
45
46 in sedentary people living with and beyond cancer: a systematic review and meta-analysis.
47
48 *BMC Cancer* 2021;21(1):308.
49
50
51 51. Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of distance-
52
53
54
55
56
57
58
59
60

- 1
2
3
4 based physical activity interventions for cancer survivors (2013-2018): We still haven't found
5
6 what we're looking for. *Cancer Treat Rev* 2018;69:188-203.
7
8
- 9 52. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and
10
11 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;
12
13 349:g7647.
14
15
- 16 53. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated
17
18 guidance and exemplars for reporting systematic reviews. *BMJ* 2021;372:n160.
19
20
21
- 22 54. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of*
23
24 *Interventions* version 6.1. Accessed March 30, 2021.
25
26 <https://training.cochrane.org/handbook/current>
27
28
- 29 55. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for rating quality
30
31 of randomized controlled trials. *Phys Ther* 2003;83:713-21.
32
33
- 34 56. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical
35
36 trials: a demographic study. *Aust J Physiother* 2009;55:129-33.
37
38
- 39 57. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta- analyses. *BMJ*
40
41 2003;327(7414):557e60.
42
43
- 44 58. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
45
46 evidence and strength of recommendations. *BMJ* 2008;336:924-6.
47
48
49
50
51
52

53 **FIGURE LEGENDS**

54 **Figure 1.** Flowchart of the study selection procedure
55
56
57
58
59
60



Appendix 1

Search Strategy Example: MEDLINE (via Ovid) search

Terms specific to Telerehabilitation

#1 exp Telemedicine/

#2 exp Telerehabilitation/

#3 (ehealth or e-health or mhealth or m-health or telehealth or tele-health or mobile health or telemetry or telerehab* or tele-rehab* or remote rehabilitation* or virtual rehabilitation* or telehomecare or tele-homecare or telecoaching or tele-coaching or telecommunication* or tele-communication* or teleconference* or tele-conference* or videoconferenc* or video-conferenc* or teleconsultation* or tele-consultation* or videoconsultation or video-consultation or telecare or tele-care).ab,ti.

#4 (telephone or smartphone or phone or mobile or video or audio or radio or internet or web* or network or on-line or computer* or sensor* or wearable or modem or email or message or media or tablet or handheld device or personal digital assistant or portable data terminal or podcast or application or App or Apps or software or virtual reality* or game*).ab,ti.

#5 exp Rehabilitation/

#6 #1 or #2 or #3 or (#4 and #5)

Terms specific to cancer

#7 exp Neoplasms/

#8 exp Carcinoma/

#9 (cancer* or tumor* or tumour* or neoplas* or malignanc* or onco* or carcinoma*).ab,ti.

#10 #7 or #8 or #9

Terms for identifying randomized controlled trials

#11 randomized controlled trial.pt.

#12 controlled clinical trial.pt.

#13 (random* or placebo or sham or trial or groups). ab,ti.

#14 #11 or #12 or #13

1
2
3 **Combination of terms to identify randomized controlled trials of telerhabilitation**
4 **programs for cancer patients and survivors**
5

6
7 #6 and #10 and #14
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review Main Document Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number Main Document Page 2, 6
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author Main Document Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review Main Document Page 12
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments NA
Support:		
Sources	5a	Indicate sources of financial or other support for the review Main Document Page 12
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known Main Document Page 3-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) Main Document Page 6-8
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review Main Document Page 6-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage Main Document Page 8-9
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated Main Document Page 8
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review Main Document Page 9

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) Main Document Page 9
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Main Document Page 9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Main Document Page 9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Main Document Page 9
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Main Document Page 10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised Main Document Page 10-11
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) Main Document Page 10-11
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) Main Document Page 10-11
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned Main Document Page 10-11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) Main Document Page 10-11
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) Main Document Page 11

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;349(jan02 1):g7647.*

BMJ Open

Telerehabilitation programmes for cancer patients and survivors: A protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058981.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Feb-2022
Complete List of Authors:	He, Yu; Shengjing Hospital of China Medical University, Department of Rehabilitation; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation Han, Xiaochai; Shengjing Hospital of China Medical University, Department of Rehabilitation Zou, Wenchen; Shengjing Hospital of China Medical University, Department of Rehabilitation Liu, Xuemin; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation Sun, Nianyi; Shanghai Fourth People's Hospital, Department of Rehabilitation; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation Zhou, Fenghua; Shengjing Hospital of China Medical University, Department of Rehabilitation; Second Clinical College China Medical University, Department of Physical Medicine and Rehabilitation
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Oncology, Sports and exercise medicine, Evidence based practice, Health services research
Keywords:	REHABILITATION MEDICINE, ONCOLOGY, EDUCATION & TRAINING (see Medical Education & Training), HEALTH SERVICES ADMINISTRATION & MANAGEMENT, SPORTS MEDICINE

SCHOLARONE™
Manuscripts

Telerehabilitation programmes for cancer patients and survivors: A protocol for a systematic review

Yu He,^{1, 2} Xiaochai Han,¹ Wenchen Zou,¹ Xuemin Liu,² Nianyi Sun,^{3, 2} Fenghua Zhou^{1, 2*}

¹Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang 110134, China.

²Department of Physical Medicine and Rehabilitation, The Second Clinical College, China Medical University, Shenyang 110122, China.

³Department of Rehabilitation, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

* Corresponding author

Dr. Fenghua Zhou, Department of Rehabilitation, Shengjing Hospital of China Medical University, No.16 Puhē Street, Shenyang 110134, Liaoning Province, People's Republic of China. All correspondence should be addressed to Dr. Zhou at zhoufenghua77@163.com

ABSTRACT

Introduction: The global cancer burden is a major public health problem. Cancer rehabilitation is an essential component of survivorship care for preventing

1
2
3
4 complications, decreasing symptoms, and improving functional quality of life (QOL).

5
6 In addition to preexisting challenges, the coronavirus disease 2019 (COVID-19)
7
8
9 pandemic has greatly affected cancer rehabilitation programmes and their delivery to
10
11 patients. This comprehensive systematic review will assess the efficacy and safety of
12
13 telerehabilitation on functional outcomes and QOL in cancer patients and survivors.
14

15
16 **Methods and analysis:** This study was conducted in accordance with the Preferred
17
18 Reporting Items for Systematic Review and Meta-Analysis Protocols. The following
19
20 key electronic bibliographic databases will be searched from their inception to April
21
22 2021: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature,
23
24 Cochrane Central Register of Controlled Trials, and Physiotherapy Evidence Database
25
26 (PEDro). We will include randomised controlled trials (RCTs) published in English that
27
28 examine the effects of telerehabilitation programmes on cancer patients and survivors.
29
30 The terms ‘telerehabilitation’, ‘neoplasm’, ‘RCT’, and their analogous terms will be
31
32 used in our search strategy. Two reviewers will independently complete the study
33
34 screening, selection, data extraction, and quality rating. The PEDro scale will be used
35
36 to assess the methodological quality of the included studies. Narrative or quantitative
37
38 synthesis will be conducted on the basis of the final data. The planned start and end
39
40 dates for the study are 1 March 2021 and 1 May 2022, respectively.
41
42
43
44
45
46
47
48
49

50
51 **Ethics and dissemination:** Ethical approval will not be required for this review, and
52
53 the results will be disseminated in peer-reviewed journals.
54

55
56 **Registration details:** PROSPERO (international prospective register of systematic
57
58 review) registration number CRD42021243467.
59
60

Strengths and limitations of this study

- This protocol and the final review will be developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis and recommendations from the *Cochrane Handbook for Systematic Reviews of Interventions*.
- Five key databases will be searched: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, and Physiotherapy Evidence Database.
- Two reviewers will independently complete the study screening, selection, data extraction, and quality rating. Possible disagreements will be resolved via discussions or consultations with a third author.
- Different types, sites, and stages of cancer and anticancer treatments may lead to a large degree of heterogeneity.

INTRODUCTION

Cancer ranks as the second-leading cause of death and is an important barrier to increasing life expectancy worldwide.^{1, 2} The magnitude of cancer is rapidly growing globally, and there were an estimated 19.3 million new cancer cases and 10.0 million cancer deaths worldwide in 2020.² The global cancer burden is predicted to be 22.2 and 28.4 million new cases in 2030 and 2040, respectively.^{2, 3}

Cancer diagnosis, progression, and aggressive treatment often cause functional

1
2
3
4 impairment and disability in both cancer patients and survivors. Physical or
5
6 psychological injury may lead to decreased health-related quality of life (QOL) in this
7
8 population.⁴ Cancer rehabilitation, which is an essential component of survivorship care,
9
10 is needed to prevent complications, decrease symptoms, improve functioning and QOL,
11
12 attain independence, and improve prognosis.⁵⁻⁷ However, several challenges hinder the
13
14 expansion of traditional face-to-face cancer rehabilitation, particularly in developing
15
16 countries.^{7, 8} Rehabilitation programmes are often long in duration and resource
17
18 intensive, and access to cancer rehabilitation services is limited because of the lack of
19
20 specialised providers (most of whom are clustered in tertiary care centres), as well as
21
22 travel burden, financial burden, time constraints, physical limitations, psychological
23
24 and emotional burden, and other hardships.⁷⁻¹² A possible solution to address these
25
26 challenges is to provide telerehabilitation services.
27
28
29
30
31
32
33
34

35 As a domain of telehealth, telerehabilitation uses of a variety of information and
36
37 communication technologies (ICTs) to deliver rehabilitation services to people over
38
39 long distances, thus closing geographic, physical, and motivational gaps.^{13, 14}
40
41 Telerehabilitation services can include evaluation, assessment, monitoring, prevention,
42
43 intervention, supervision, education, consultation, and coaching.^{13, 14} The ICT used in
44
45 telerehabilitation may integrate but are not limited to email programmes, text
46
47 messaging, telephone follow-up, video and audio conferencing, wearable technologies,
48
49 sensor technologies, mobile health applications, patient portals or platforms, virtual
50
51 reality programmes, therapeutic gaming technologies, and robotics.¹³⁻¹⁶ There has been
52
53 increasing interest in the use of this burgeoning field of telerehabilitation services as
54
55
56
57
58
59
60

1
2
3
4 technologies continue to evolve.¹⁴ Many examples in the current literature have
5
6 explored the acceptability, feasibility, efficacy, and cost-effectiveness of
7
8 telerehabilitation in neurological,¹⁷⁻¹⁹ cardiopulmonary,²⁰⁻²³ musculoskeletal,²⁴⁻²⁶ and
9
10 postoperative^{27, 28} rehabilitation services, thus showing that this field is promising.
11
12
13

14 In recent years, there have been a proliferation of studies on telehealth-related
15
16 oncology, most of which focus on the feasibility and technical properties of
17
18 technologies, diagnosis and treatment approaches, user experience, or symptom
19
20 monitoring.²⁹ Earlier systematic reviews regarding telehealth interventions in this
21
22 territory involved application research on current technology and services,^{30, 31}
23
24 acceptability studies,³² studies on self-management programmes,^{33, 34} and studies on
25
26 certain types of tumours.³⁵⁻³⁸ In addition, clinical effectiveness measures were mostly
27
28 psychosocial, symptomatic, or QOL related.³⁹⁻⁴⁵
29
30
31
32
33
34

35 However, only a small amount of evidence exists on the effectiveness of
36
37 telerehabilitation programmes for cancer patients and survivors, and most pieces of
38
39 evidence have diverse emphasis. Two studies systematically reviewed evidence on the
40
41 benefits of psychoeducational interventions that use telecommunication technologies
42
43 for cancer patients^{46, 47} and showed promising findings. A recent review explored and
44
45 confirmed the usefulness of the telehealth approach for occupational therapy practice
46
47 in cancer survivors,⁴⁸ but two other studies on remotely delivered physical activity
48
49 showed results that were not as positive.^{49, 50} Additionally, the coronavirus disease 2019
50
51 (COVID-19) pandemic has broadly disrupted medical care and expedited the transition
52
53 of cancer rehabilitation programmes to a remote-delivery format,⁵¹ thus increasing the
54
55
56
57
58
59
60

1
2
3
4 urgency of understanding the efficacy and safety of such a model. Given the current
5
6 status of research in this field, this comprehensive systematic review aims to study the
7
8 efficacy and safety of telerehabilitation on functional outcomes and QOL in cancer
9
10 patients and survivors to inform future models of care for cancer rehabilitation.
11
12

13 14 **METHODS**

15 16 **Study registration**

17
18 The planned start and end dates for the study are 1 March 2021 and 1 May 2022,
19
20 respectively. This protocol has been registered on PROSPERO (registration number:
21
22 CRD42021243467) and was developed according to the Preferred Reporting Items for
23
24 Systematic Review and Meta-Analysis (PRISMA) Protocols.⁵² The final systematic
25
26 review will be conducted in line with the PRISMA statement⁵³ and the guidance of the
27
28 *Cochrane Handbook for Systematic Reviews of Interventions*.⁵⁴
29
30
31
32
33

34 35 **Inclusion criteria for study selection**

36
37 Studies will be included in the final review if they meet the inclusion criteria defined
38
39 by PICO elements (P = participant, I = intervention, C = comparison, and O = outcomes)
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
55 and the types of studies. Table 1 shows a summary of the inclusion criteria.

56 57 **Types of participants**

58
59
60
Adult cancer patients or survivors (≥ 18 years of age) will be considered irrespective of
sex, race, site of cancer, type and stage of cancer, and type of anticancer treatment
received. Cancer survivors refer to those who have been diagnosed with cancer, have
successfully completed curative treatments, or have transitioned to maintenance or
prophylactic therapy.^{56, 57}

Types of interventions

Participants in the experimental group will receive telerehabilitation programmes. In the context of this study, telerehabilitation is considered as any rehabilitation programme delivered by health care professionals (physical, occupational, or speech therapists; exercise trainers; neuropsychologists; etc.) via ICT to cancer patients and survivors. Telerehabilitation can be delivered to a satellite healthcare centre or directly into the patient's home and can be performed in a group or individually. Telerehabilitation programmes that use 'store and forward'/asynchronous or real-time/synchronous interaction will be included. Telehealth interventions for the purposes of patient education or communication, self-administered management without the supervision of healthcare professionals, remote symptoms, or monitoring of physiological parameters alone (i.e., telemonitoring) will be excluded.

Types of comparator(s)/control

We will include studies that compare telerehabilitation programmes with face-to-face rehabilitation treatments, such as centre-based (outpatient) rehabilitation, inpatient rehabilitation, home visits, or no rehabilitation control.

Types of outcome measures

Primary outcomes

1. Health-related QOL was assessed using validated measures. Examples include the Functional Assessment of Cancer Therapy General and related site-specific cancer module, The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire version 3.0, and related site-specific cancer module,

1
2
3
4 Short Form (36) Health Survey, Patient-Reported Outcomes Measurement Information
5
6 System (PROMIS) 29, and PROMIS Cancer Function 3D Profile.
7
8

9 2. Physical function was assessed using the validated measures, e.g., the timed up-and-
10
11 go test and six-minute walk test for testing physical performance; the cardiopulmonary
12
13 exercise test and moderate-to-vigorous physical activity test for testing functional
14
15 capacity; and impairment measures for testing range of motion, muscle strength, and
16
17 flexibility.
18
19

20 21 22 *Secondary outcomes*

23
24 Cancer-related symptoms (pain, fatigue, nausea/vomiting, dyspnoea, sleep disturbances,
25
26 appetite loss, constipation, and diarrhoea), anthropometrics, psychometric properties,
27
28 biomarker analysis, survivorship, adverse events, patient satisfaction, and compliance.
29

30
31 These outcomes should be assessed using validated tests and scales.
32
33

34 35 **Types of studies**

36
37 Randomised controlled trials (RCTs) reported in English and published as full text will
38
39 be included. Studies will be excluded if they are quasirandomised trials, animal research,
40
41 uncontrolled trials, case reports, conference proceedings, abstracts, dissertations, or
42
43 reports in books or have no available data for analysis.
44
45
46
47

48 49 **Search methods for the identification of studies**

50
51 The following key electronic bibliographic databases will be searched from inception
52
53 to April 2021: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health
54
55 Literature, Cochrane Central Register of Controlled Trials, and the Physiotherapy
56
57 Evidence Database (PEDro). RCTs that evaluate the effectiveness of telerehabilitation
58
59
60

1
2
3
4 programmes for cancer patients and survivors by setting the comparators/controls
5
6 mentioned above will be included. The strategy will search for ‘telerehabilitation’ AND
7
8 ‘neoplasms’ AND ‘RCTs’. For the ‘intervention’, ‘participants’, and ‘study design’
9
10 concept, we will combine synonyms and MeSH terms with the ‘OR’ operator. Online
11
12 Supplemental Material Appendix 1 shows the proposed search strategy for MEDLINE
13
14 via Ovid. This strategy will be adapted for use with other databases. In addition, we
15
16 will check the reference lists of all included trials and relevant systematic reviews to
17
18 identify potentially eligible studies.
19
20
21
22
23

24 **Data collection**

25 **Study selection**

26
27 The retrieved records will be imported into the bibliographic software EndNote X9.
28
29 Any duplicates will be identified and removed using EndNote. Two review authors (YH
30
31 and NS) will independently screen the titles, abstracts, and keywords of the remaining
32
33 articles by using predefined criteria. After preliminary screening, we will retrieve the
34
35 full text of all potentially eligible articles, and two review authors (YH and NS) will
36
37 independently review them in detail. The explicit reasons for the exclusion of ineligible
38
39 studies will be recorded. Any disagreement will be resolved via discussions or
40
41 consultations with a third author (FZ). Figure 1 shows a flowchart of the selection
42
43 procedure.
44
45
46
47
48
49
50
51

52 **Data extraction and management**

53
54 Two review authors (YH and NS) will use a predesigned data collection Excel form to
55
56 independently extract the following data from the included studies:
57
58
59
60

- 1
2
3
4 1. General information: article title, journal, publication year, first author,
5
6 corresponding author, country of study, aim of study, trial registration, study funding
7
8 source, and possible conflicts of interest
9
10
- 11 2. Study characteristics: study design, randomisation method, blinding method,
12
13 allocation concealment, and completeness of outcome data
14
15
- 16 3. Participants: sample size, baseline participant characteristics, cancer site, type and
17
18 stage of cancer, type of anticancer treatment, and comorbidities
19
20
- 21 4. Interventions: type, frequency, intensity and duration for telerehabilitation, and
22
23 comparators
24
25
- 26 5. Outcomes: outcome measurements, time points reported, follow-up duration, and
27
28 adverse events
29
30
31

32 **Methodological quality assessment**

34 Two review authors (YH and NS) will independently assess the methodological quality
35
36 of each selected study by using the PEDro scale.⁵⁸ Possible disagreements will be
37
38 resolved via discussions or consultations with a third author (FZ). The PEDro scale is
39
40 considered a valid and reliable measure of the methodological quality of RCTs in
41
42 physiotherapy and has moderate interrater reliability.^{58, 59} This scale consists of 11
43
44 criteria. Considering that the 1st item is not utilised in calculating the score, the scale
45
46 has a possible range of 0–10, with higher scores indicating a higher quality. On this
47
48 scale, the cutoff for high-quality methodology is ≥ 6 points.⁵⁸
49
50
51
52
53
54

55 **Data analysis and synthesis**

56
57
58 Cochrane Review Manager version 5 will be used for the meta-analysis. In our study,
59
60

1
2
3
4 a meta-analysis concerning the effect of telerehabilitation programmes will be
5
6 conducted if at least two studies used homogeneous outcome measures or measured
7
8 similar constructs.
9

10
11 The summary results are computed in different ways according to the data type.
12
13 For continuous data, standardised mean differences and 95% confidence intervals
14
15 (CI) will be computed. For dichotomous data, odds ratios and 95% CIs will be
16
17 computed.
18
19
20
21

22 The chi-squared test and I^2 statistic will be used to assess heterogeneity across
23
24 studies.^{54, 60} If $p > 0.1$ and $I^2 < 50\%$, a fixed-effect model will be adopted for data
25
26 combination. If $p > 0.1$ and $I^2 \geq 50\%$, a random-effect model will be adopted for data
27
28 combination, and obvious heterogeneity will be considered between the studies. If $p \leq$
29
30 0.1, statistical significance will be considered, and a subgroup analysis or a narrative
31
32 description will be performed.⁵⁴ The narrative description will synthesise findings from
33
34 multiple studies and primarily adopt text and words to summarise and explain the
35
36 findings from the included studies.^{54, 61}
37
38
39
40
41
42

43 When sufficient data are available, prespecified subgroups will be established on
44
45 the basis of gender; comorbid condition; type, frequency, intensity, and duration of
46
47 telerehabilitation programmes; and site, type, and stage of cancer to explore the factors
48
49 that might be related to the strength of the effect. If the data permit, sensitivity analyses
50
51 will be performed to examine the robustness and reliability of the results by omitting
52
53 specific trials from the overall analysis.
54
55
56
57

58 If more than 10 trials are included in the meta-analysis, we will construct a funnel
59
60

1
2
3
4 plot to explore the potential publication bias.
5

6 The overall quality of each summarised evidence will be evaluated using the
7
8 Grading of Recommendations Assessment, Development and Evaluation (GRADE)
9
10 system at four levels: high, moderate, low, or very low.⁶² Two review authors (YH and
11
12 NS) will independently assess the quality of the evidence by using GRADEpro software
13
14 (https://grade.pro.org), and possible discrepancies will be resolved via discussions or
15
16 consultations with a third author (FZ).
17
18
19
20
21

22 **Patient and public involvement**

23
24 This systematic review protocol does not directly involve the patients or general public.
25
26 Data will be collected from published articles retrieved from the main databases and
27
28 manually searched.
29
30
31

32 **Ethics and dissemination**

33
34 Ethical approval will not be required for this review protocol. The results of the final
35
36 review will be disseminated in peer-reviewed journals.
37
38
39

40 **DISCUSSION**

41
42 The COVID-19 pandemic has prompted calls for the accelerated introduction of
43
44 alternative models of cancer rehabilitation service delivery, including home-based
45
46 telerehabilitation.^{9, 51} In the realm of cancer rehabilitation, this new care model has great
47
48 potential to facilitate access to services; allow the continuity of rehabilitation; improve
49
50 care equity; and counteract geographic, demographic, and socioeconomic barriers.
51
52 However, this is likely to reveal new disparities between healthcare professionals and
53
54 patients. For example, the reliance on technology is central to the delivery of
55
56
57
58
59
60

1
2
3
4 telerehabilitation, and creative ways to overcome this obstacle maybe needed.⁹ In
5
6 addition, the manner in which to conduct an adapted virtual physical examination also
7
8
9 needs particular attention.^{9, 63}
10

11 The final review will systematically and comprehensively assess the efficacy and
12
13 safety of telerehabilitation programmes on functional outcomes and QOL in patients
14
15 with cancer and survivors. This protocol provides the current status of research in this
16
17 field, and we hope that the final review will be helpful in supporting decision-making
18
19 processes related to health policies and rehabilitation programmes.
20
21
22
23
24
25
26

27 **Acknowledgments** We thank the anonymous reviewers for their helpful comments.
28

29 **Contributors** YH, NS and FZ contributed to the conception and design of the study.
30
31 NS registered the protocol in the PROSPERO database. YH drafted the protocol. FZ
32
33 revised the protocol critically for important intellectual content. XH, WZ and XL
34
35 designed the search strategy. YH, XH, WZ, XL, NS and FZ participated in the design
36
37 of data acquisition, analysis and interpretation. All authors have read and approved the
38
39 final protocol. FZ is the guarantor of this protocol.
40
41
42
43
44

45 **Funding** This research did not receive any specific grant from funding agencies in the
46
47 public, commercial, or not-for-profit sectors.
48
49

50 **Competing interests:** We declare that there is no conflict of interest regarding the
51
52 publication of this protocol.
53
54

55 **Patient consent for publication** Not required.
56
57

58 **Ethical approval:** Ethical approval will not be required for the performance of this
59
60

1
2
3
4 protocol for a systematic review.
5

6 **Data sharing** No additional data are available.
7
8
9

10
11 **REFERENCES**
12

- 13
14 1. World Health Organization (WHO). Cancer. Available:
15
16 <https://www.who.int/zh/news-room/fact-sheets/detail/cancer> [Accessed 30 March
17
18 2021].
19
20
21
22 2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN
23
24 estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.
25
26 *CA Cancer J Clin* 2021;71(3):209-49.
27
28
29
30 3. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human
31
32 development index (2008-2030): a population-based study. *Lancet Oncol*
33
34 2012;13(8):790-801.
35
36
37
38 4. Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an
39
40 essential component of quality care and survivorship. *CA Cancer J Clin*
41
42 2013;63(5):295-317.
43
44
45
46 5. Alfano CM, Ganz PA, Rowland JH, et al. Cancer survivorship and cancer
47
48 rehabilitation: revitalizing the link. *J Clin Oncol* 2012;30(9):904-6.
49
50
51
52 6. Stout NL, Silver JK, Raj VS, et al. Toward a national initiative in cancer
53
54 rehabilitation: recommendations from a subject matter expert group. *Arch Phys*
55
56 *Med Rehabil* 2016;97(11):2006-15.
57
58
59
60 7. Stout NL, Santa Mina D, Lyons KD, et al. A systematic review of rehabilitation

- 1
2
3
4 and exercise recommendations in oncology guidelines. *CA Cancer J Clin*
5
6 2021;71(2):149-75.
7
8
9 8. Anwar SL, Adistyawan G, Wulaningsih W, et al. Rehabilitation for cancer
10 survivors: how we can reduce the healthcare service inequality in low- and middle-
11 income countries. *Am J Phys Med Rehabil* 2018;97(10):764-71.
12
13
14 9. Chang P, Asher A. Cancer telerehabilitation. *Phys Med Rehabil Clin N Am*
15 2021;32(2):277-89.
16
17
18 10. Fillon M. Patients with advanced-stage cancer may benefit from telerehabilitation.
19 *CA Cancer J Clin* 2019;69(5):349-50.
20
21
22 11. Cheville AL, Mustian K, Winters-Stone K, et al. Cancer rehabilitation: an overview
23 of current need, delivery models, and levels of care. *Phys Med Rehabil Clin N Am*
24 2017;28(1):1-17.
25
26
27 12. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect
28 on physical and mental health-related quality of life among US cancer survivors.
29 *Cancer* 2016;122(8):283-9.
30
31
32 13. Richmond T, Peterson C, Cason J, et al. American telemedicine association's
33 principles for delivering telerehabilitation services. *Int J Telerehabil* 2017;9(2):63-
34 8.
35
36
37 14. Galea MD. Telemedicine in rehabilitation. *Phys Med Rehabil Clin N Am*
38 2019;30(2):473-83.
39
40
41
42 15. Tenforde AS, Hefner JE, Kodish-Wachs JE, et al. Telehealth in physical medicine
43 and rehabilitation: a narrative review. *PM R* 2017;9(5S):S51-8.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16. Pramuka M, van Roosmalen L. Telerehabilitation technologies: accessibility and usability. *Int J Telerehabil* 2009;1(1):85-98.
17. Laver KE, Adey-Wakeling Z, Crotty M, et al. Telerehabilitation services for stroke. *Cochrane Database Syst Rev* 2020;1(1):CD010255.
18. Hailey D, Roine R, Ohinmaa A, et al. The status of telerehabilitation in neurological applications. *J Telemed Telecare* 2013;19(6):307-10.
19. Ownsworth T, Arnautovska U, Beadle E, et al. Efficacy of telerehabilitation for adults with traumatic brain injury: a systematic review. *J Head Trauma Rehabil* 2018;33(4):E33-46.
20. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. *Cochrane Database Syst Rev* 2021;1(1):CD013040.
21. Taito S, Yamauchi K, Kataoka Y. Telerehabilitation in subjects with respiratory disease: a scoping review. *Respir Care* 2021;66(4):686-98.
22. Hwang R, Bruning J, Morris N, et al. A systematic review of the effects of telerehabilitation in patients with cardiopulmonary diseases. *J Cardiopulm Rehabil Prev* 2015;35(6):380-9.
23. Subedi N, Rawstorn JC, Gao L, et al. Implementation of telerehabilitation interventions for the self-management of cardiovascular disease: systematic review. *JMIR Mhealth Uhealth* 2020;8(11):e17957.
24. Cottrell MA, Galea OA, O'Leary SP, et al. Real-time telerehabilitation for the treatment of musculoskeletal conditions is effective and comparable to standard practice: a systematic review and meta-analysis. *Clin Rehabil* 2017;31(5):625-38.

- 1
2
3
4 25. Srikesavan C, Bryer C, Ali U, et al. Web-based rehabilitation interventions for
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Srikesavan C, Bryer C, Ali U, et al. Web-based rehabilitation interventions for
people with rheumatoid arthritis: a systematic review. *J Telemed Telecare*
2019;25(5):263-75.
26. Xie SH, Wang Q, Wang LQ, et al. Effect of internet-based rehabilitation programs
on improvement of pain and physical function in patients with knee osteoarthritis:
systematic review and meta-analysis of randomized controlled trials. *J Med*
Internet Res 2021;23(1):e21542.
27. van Egmond MA, van der Schaaf M, Vredeveld T, et al. Effectiveness of
physiotherapy with telerehabilitation in surgical patients: a systematic review and
meta-analysis. *Physiotherapy* 2018;104(3):277-98.
28. Jiang S, Xiang J, Gao X, et al. The comparison of telerehabilitation and face-to-
face rehabilitation after total knee arthroplasty: a systematic review and meta-
analysis. *J Telemed Telecare* 2018;24(4):257-62.
29. Rising KL, Ward MM, Goldwater JC, et al. Framework to advance oncology-
related telehealth. *JCO Clin Cancer Inform* 2018;2:1-11.
30. Ayyoubzadeh SM, R Niakan Kalhori S, Shirkhoda M, et al. Supporting colorectal
cancer survivors using eHealth: a systematic review and framework suggestion.
Support Care Cancer 2020;28(8):3543-55.
31. Schaffer K, Panneerselvam N, Loh KP, et al. Systematic review of randomized
controlled trials of exercise interventions using digital activity trackers in patients
with cancer. *J Natl Compr Canc Netw* 2019;17(1):57-63.
32. Sotirova MB, McCaughan EM, Ramsey L, et al. Acceptability of online exercise-

- 1
2
3
4 based interventions after breast cancer surgery: systematic review and narrative
5
6 synthesis. *J Cancer Surviv* 2021;15(2):281-310.
7
8
- 9 33. Huang J, Han Y, Wei J, et al. The effectiveness of the Internet-based self-
10 management program for cancer-related fatigue patients: a systematic review and
11 meta-analysis. *Clin Rehabil* 2020;34(3):287-98.
12
13
- 14 34. Xu A, Wang Y, Wu X. Effectiveness of e-health based self-management to
15 improve cancer-related fatigue, self-efficacy and quality of life in cancer patients:
16 Systematic review and meta-analysis. *J Adv Nurs* 2019;75(12):3434-47.
17
18
- 19 35. Triberti S, Savioni L, Sebri V, et al. eHealth for improving quality of life in breast
20 cancer patients: a systematic review. *Cancer Treat Rev* 2019;74:1-14.
21
22
- 23 36. Dorri S, Asadi F, Olfatbakhsh A, et al. A systematic review of electronic health
24 (eHealth) interventions to improve physical activity in patients with breast cancer.
25 *Breast Cancer* 2020;27(1):25-46.
26
27
- 28 37. Chen YY, Guan BS, Li ZK, et al. Effect of telehealth intervention on breast cancer
29 patients' quality of life and psychological outcomes: a meta-analysis. *J Telemed*
30 *Telecare* 2018;24(3):157-67.
31
32
- 33 38. Pang L, Liu Z, Lin S, et al. The effects of telemedicine on the quality of life of
34 patients with lung cancer: a systematic review and meta-analysis. *Ther Adv*
35 *Chronic Dis* 2020;11:2040622320961597.
36
37
- 38 39. Seiler A, Klaas V, Tröster G, et al. eHealth and mHealth interventions in the
39 treatment of fatigued cancer survivors: a systematic review and meta-analysis.
40 *Psychooncology* 2017;26(9):1239-53.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 40. Fridriksdottir N, Gunnarsdottir S, Zoëga S, et al. Effects of web-based
5
6 interventions on cancer patients' symptoms: review of randomized trials. *Support*
7
8 *Care Cancer* 2018;26(2):337-51.
9
10
11 41. Hernandez Silva E, Lawler S, Langbecker D. The effectiveness of mHealth for self-
12
13 management in improving pain, psychological distress, fatigue, and sleep in cancer
14
15 survivors: a systematic review. *J Cancer Surviv* 2019;13(1):97-107.
16
17
18 42. Buneviciene I, Mekary RA, Smith TR, et al. Can mHealth interventions improve
19
20 quality of life of cancer patients? a systematic review and meta-analysis. *Crit Rev*
21
22 *Oncol Hematol* 2021;157:103123.
23
24
25 43. Agboola SO, Ju W, Elfiky A, et al. The effect of technology-based interventions
26
27 on pain, depression, and quality of life in patients with cancer: a systematic review
28
29 of randomized controlled trials. *J Med Internet Res* 2015;17(3):e65.
30
31
32 44. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality
33
34 of life of cancer patients: a systematic review and meta-analysis. *Telemed J E*
35
36 *Health* 2018;24(6):397-405.
37
38
39 45. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality
40
41 of life of cancer survivors: a systematic review and meta-analysis. *Health*
42
43 *Informatics J* 2020;26(2):1060-78.
44
45
46 46. Bártolo A, Pacheco E, Rodrigues F, et al. Effectiveness of psycho-educational
47
48 interventions with telecommunication technologies on emotional distress and
49
50 quality of life of adult cancer patients: a systematic review. *Disabil Rehabil*
51
52 2019;41(8):870-78.
53
54
55
56
57
58
59
60

- 1
2
3
4 47. Wang Y, Lin Y, Chen J, et al. Effects of internet-based psycho-educational
5 interventions on mental health and quality of life among cancer patients: a
6 systematic review and meta-analysis. *Support Care Cancer* 2020;28(6):2541-52.
7
8
9
10
11 48. Hwang NK, Jung YJ, Park JS. Information and communications technology-based
12 telehealth approach for occupational therapy interventions for cancer survivors: a
13 systematic review. *Healthcare (Basel)* 2020;8(4):355.
14
15
16
17
18
19 49. Ibeggazene S, Turner R, Rosario D, et al. Remote interventions to improve exercise
20 behaviour in sedentary people living with and beyond cancer: a systematic review
21 and meta-analysis. *BMC Cancer* 2021;21(1):308.
22
23
24
25
26
27 50. Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of
28 distance-based physical activity interventions for cancer survivors (2013-2018):
29 we still haven't found what we're looking for. *Cancer Treat Rev* 2018;69:188-203.
30
31
32
33
34
35 51. Nekhlyudov L, Duijts S, Hudson SV, et al. Addressing the needs of cancer
36 survivors during the COVID-19 pandemic. *J Cancer Surviv* 2020;14(5):601-6.
37
38
39
40
41 52. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
42 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
43 explanation. *BMJ* 2015; 349:g7647.
44
45
46
47
48 53. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration:
49 updated guidance and exemplars for reporting systematic reviews. *BMJ*
50 2021;372:n160.
51
52
53
54
55
56 54. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic
57
58 Reviews of Interventions version 6.1. Available:
59
60

- <https://training.cochrane.org/handbook/current> [Accessed 30 March 2021].
55. Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. *ACP J Club* 1995;123(3):A12-3.
56. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin* 2019;69(5):363-85.
57. Surbone A, Annunziata MA, Santoro A, et al. Cancer patients and survivors: changing words or changing culture? *Ann Oncol* 2013;24(10):2468-71.
58. Maher CG, Sherrington C, Herbert RD, et al. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Phys Ther* 2003;83:713-21.
59. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. *Aust J Physiother* 2009;55:129-33.
60. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557e60.
61. Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme version. Bailrigg Lancaster Univ. 2006;1:1-92.
62. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
63. Verduzco-Gutierrez M, Bean AC, Tenforde AS, et al. How to conduct an outpatient telemedicine rehabilitation or prehabilitation visit. *PM R* 2020;12(7):714-20.

FIGURE LEGENDS

1
2
3
4 **Figure 1.** Flowchart of the study selection procedure
5


6 **TABLE LEGENDS**
7

8
9 **Table 1.** Eligibility criteria
10

11
12
13 **Table 1.** Eligibility criteria
14

PICOS	
Participant	Adult cancer patients or survivors.
Intervention	Telerehabilitation (e.g. remotely guided on-line or virtual reality motor training, occupational exercises at home utilizing sensor technologies.)
Comparison	Face to face rehabilitation, usual care.
Outcome	Primary outcomes: Health-related QOL, physical function Secondary outcomes: Cancer-related symptoms, anthropometrics, psychometric properties, biomarker analysis, survivorship, adverse events, patient satisfaction, and compliance, etc.
Study design	RCT reported in English.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Appendix 1

Search Strategy Example: MEDLINE (via Ovid) search

Terms specific to Telerehabilitation

#1 exp Telemedicine/

#2 exp Telerehabilitation/

#3 (ehealth or e-health or mhealth or m-health or telehealth or tele-health or mobile health or telemetry or telerehab* or tele-rehab* or remote rehabilitation* or virtual rehabilitation* or telehomecare or tele-homecare or telecoaching or tele-coaching or telecommunication* or tele-communication* or teleconference* or tele-conference* or videoconferenc* or video-conferenc* or teleconsultation* or tele-consultation* or videoconsultation or video-consultation or telecare or tele-care).ab,ti.

#4 (telephone or smartphone or phone or mobile or video or audio or radio or internet or web* or network or on-line or computer* or sensor* or wearable or modem or email or message or media or tablet or handheld device or personal digital assistant or portable data terminal or podcast or application or App or Apps or software or virtual reality* or game*).ab,ti.

#5 exp Rehabilitation/

#6 #1 or #2 or #3 or (#4 and #5)

Terms specific to cancer

#7 exp Neoplasms/

#8 exp Carcinoma/

#9 (cancer* or tumor* or tumour* or neoplas* or malignanc* or onco* or carcinoma*).ab,ti.

#10 #7 or #8 or #9

Terms for identifying randomized controlled trials

#11 randomized controlled trial.pt.

#12 controlled clinical trial.pt.

#13 (random* or placebo or sham or trial or groups). ab,ti.

#14 #11 or #12 or #13

1
2
3 **Combination of terms to identify randomized controlled trials of telerhabilitation**
4 **programs for cancer patients and survivors**
5

6
7 #6 and #10 and #14
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review Main Document Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number Main Document Page 2, 6
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author Main Document Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review Main Document Page 13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments NA
Support:		
Sources	5a	Indicate sources of financial or other support for the review Main Document Page 13
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known Main Document Page 3-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) Main Document Page 6-8
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review Main Document Page 6-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage Main Document Page 8-9
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated Main Document Page 8-9
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review Main Document Page 9-10

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) Main Document Page 9-10
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Main Document Page 9-10
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Main Document Page 9-10
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Main Document Page 9-10
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Main Document Page 10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised Main Document Page 10-12
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) Main Document Page 10-12
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) Main Document Page 10-12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned Main Document Page 10-12
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) Main Document Page 10-12
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) Main Document Page 12

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;349(jan02 1):g7647.*